Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Tigecycline Use in Pneumonia Treatment

Evidence Against Tigecycline Use

  • Tigecycline should not be used for the treatment of pneumonia in patients with COPD due to higher mortality rates and treatment failure compared to alternative therapies 1
  • Clinical guidelines note "no experience in pneumonia for tigecycline" when discussing treatment options for various pathogens in pneumonia 2, 3
  • Tigecycline monotherapy has demonstrated higher rates of treatment failure compared to alternative therapies for respiratory infections 1
  • The European Respiratory Society recommends aminopenicillin ± macrolide, aminopenicillin/β-lactamase inhibitor ± macrolide, non-antipseudomonal cephalosporin (cefotaxime or ceftriaxone) ± macrolide, levofloxacin or moxifloxacin, and penicillin G ± macrolide as first-line treatments for pneumonia in COPD patients 2
  • For hospitalized patients with community-acquired pneumonia in COPD, the above options are recommended in alphabetical order 2, 3

Special Considerations for COPD Patients

  • The Global Initiative for Chronic Obstructive Lung Disease recommends antibiotics in exacerbations of COPD when patients present with increased dyspnea, increased sputum volume, and increased sputum purulence 4
  • The European Respiratory Society suggests considering antibiotics for exacerbations in patients with severe COPD, even if they don't have all three symptoms 4
  • First-choice antibiotics for COPD patients include amoxicillin or tetracycline based on least chance of harm and wide clinical experience 5
  • In case of hypersensitivity, a tetracycline or macrolide such as azithromycin, clarithromycin, erythromycin, or roxithromycin is recommended in areas with low pneumococcal macrolide resistance 5

Important Warnings and Monitoring

  • Tigecycline should only be used when the minimum inhibitory concentration (MIC) is ≤2 mg/L 1
  • Common adverse effects of tigecycline include nausea, vomiting, and diarrhea 1
  • Tigecycline performs poorly in bacteremic patients due to low plasma concentrations 1